← All trials
NCT07298005
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 28, 2026
- Primary completion
- Feb 28, 2027
- Completion date
- Mar 31, 2027
- First posted
- Dec 22, 2025
- Last posted
- Dec 22, 2025
- Enrollment
- 80
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of AmsterdamLead sponsor
- University of AmsterdamSponsor investigator
- Khondrion BVCollaborator
- ZonMw: The Netherlands Organisation for Health Research and DevelopmentCollaborator
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.